RFdiffusion2 for Molecular Interfaces designs zinc-dependent proteases for peptide-bond hydrolysis. The primary paper reports cleavage at the targeted bond in 36% of 135 designs and selected designs that cleave disease-associated proteins in vitro. These biochemical results do not establish therapeutic efficacy.
Technology: RFdiffusion2 for Molecular Interfaces (RFD2-MI); AlphaFold 3
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The source reports the study-specific result summarized here.
- Still unknown: Independent replication and broader deployment or clinical benefit are not established by this source review.
- AI role: RFD2-MI generates scaffolds around zinc catalytic and peptide-binding geometries; computational filtering guided experimental testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12667880/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary-source abstract and publication metadata reviewed; full text scope is specified in source_checks..
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Methods insert a detectable signal into protein sequences and predicted structures. For binders designed against three targets (VEGF-A, SARS-CoV-2 RBD, and PD-L1), watermarked designs matched the others in success rate and affinity. This is a proof of concept that needs to be made more robust against tampering.
Technology: SynthID Bio, AlphaFold 3 (optimized component)
Family AlphaFold 3: profile · models page
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Wet-lab tests on three targets (VEGF-A, SARS-CoV-2 RBD, PD-L1), with Adaptyv Bio helping, showed watermarked designs matched unwatermarked ones in hit rate, affinity and diversity; the phage was tested only in bacterial cultures.
- Still unknown: The watermark must become more robust against deliberate tampering, the bacteriophage work is early-stage, and the post says no single biosecurity measure is a silver bullet.
- AI role: SynthID Bio guided amino acid choice in a ProteinMPNN variant, adjusted predicted atomic coordinates, fine-tuned part of AlphaFold 3, and was integrated into Evo 2 to watermark a designed phage genome.
Evidence sources: https://deepmind.google/blog/introducing-synthid-bio/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Crystallographic fragment screening of a designed binding protein guided redesign into a fluorophore binder and a Kemp eliminase. LigandMPNN and structure-prediction models supported the design workflow; crystal structures and enzyme assays checked the resulting functions. The paper reports catalytic efficiency of 3.2 million M⁻¹ s⁻¹ for the eliminase. This entry tracks the 4 May 2026 journal version; a preprint preceded it.
Technology: LigandMPNN with Rosetta relaxation for sequence design; RaptorX and later AlphaFold 3 for structure checking
Family AlphaFold 3: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Fragment screening, crystallography and enzyme assays of redesigned proteins; reported Kemp eliminase catalytic efficiency 3,200,000 M⁻¹ s⁻¹.
- Still unknown: The reported kinetics and structural tests are within the study; independent replication was not assessed. The journal version follows an earlier preprint.
- AI role: LigandMPNN with Rosetta relaxation designed enzyme sequences; RaptorX and later AlphaFold 3 predictions checked candidate structures.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13245809/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41557-026-02125-6%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
With the Norwegian University of Life Sciences, predicted structures of honeybee vitellogenin were confirmed by electron microscopy in July 2025; AlphaFold 3 helped study its interactions with other molecules. Early evidence suggests breeding times for resilient bees could fall from months to weeks, a still preliminary claim.
Technology: AlphaFold, AlphaFold 3
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: AlphaFold-predicted vitellogenin structures were confirmed by electron microscopy in July 2025, per the post; the linked paper reports a cryo-EM structure of native honey bee vitellogenin, and the breeding-time claim comes from early trials.
- Still unknown: The breeding-time benefit (months to weeks) is preliminary and not cited to a publication, and implications for other egg-laying species are possibilities, not established findings.
- AI role: AlphaFold 3 predicted the vitellogenin structures and helped study how it binds other molecules inside the bee.
Evidence sources: https://deepmind.google/blog/breeding-healthier-and-stronger-honeybees/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-025-58575-y&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 12 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
RFD2-MI designs cysteine-nucleophile proteases that cleave peptide backbones in a sequence-dependent manner. The preprint abstract reports rate enhancements up to 3 × 10^7 and crystal structures close to design models. The journal version reports additional experiments; this draft is bounded to the preprint abstract result and does not transfer later results across versions.
Technology: RFD2-MI; ProteinMPNN; AlphaFold 3
Family ProteinMPNN: profile · models page
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The source reports the study-specific result summarized here.
- Still unknown: Independent replication and broader deployment or clinical benefit are not established by this source review.
- AI role: RFD2-MI generates catalytic protein structures; sequence design and structure prediction support experimental selection.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12668006/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary-source abstract and publication metadata reviewed; full text scope is specified in source_checks..
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
It predicts joint structures of proteins, nucleic acids, small molecules and ions. DeepMind and Isomorphic Labs report at least 50% greater accuracy than existing methods for protein interactions with other molecules. Free for non-commercial research through the AlphaFold Server.
Technology: AlphaFold 3
Family AlphaFold 3: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Higher accuracy than docking tools for protein–ligand interactions, than nucleic-acid-specific predictors for protein–nucleic acid interactions, and than AlphaFold-Multimer v2.3 for antibody–antigen prediction.
- Still unknown: Accuracy on new experimental targets beyond the benchmarks is not described in the abstract.
- AI role: A diffusion-based architecture predicting joint structures of proteins, nucleic acids, small molecules, ions and modified residues.
Evidence sources: https://doi.org/10.1038/s41586-024-07487-w
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 17949 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 5/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.